|
1
|
El-Serag HB: Epidemiology of viral
hepatitis and hepatocellular carcinoma. Gastroenterology.
142:1264–1273. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
de Lope CR, Tremosini S, Forner A, et al:
Management of HCC. J Hepatol. 56(Suppl 1): S75–S87. 2012.
|
|
3
|
El-Serag HB: Hepatocellular carcinoma. N
Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chan HL and Sung JJ: Hepatocellular
carcinoma and hepatitis B virus. Semin Liver Dis. 26:153–161. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Perz JF, Armstrong GL, Farrington LA,
Hutin YJ and Bell BP: The contributions of hepatitis B virus and
hepatitis C virus infections to cirrhosis and primary liver cancer
worldwide. J Hepatol. 45:529–538. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Belongia EA, Costa J, Gareen IF, et al:
NIH consensus development statement on management of hepatitis B.
NIH Consens State Sci Statements. 25:1–29. 2008.PubMed/NCBI
|
|
7
|
Nishikawa H, Arimoto A, Wakasa T, Kita R,
Kimura T and Osaki Y: Effect of transcatheter arterial
chemoembolization prior to surgical resection for hepatocellular
carcinoma. Int J Oncol. 42:151–160. 2013.
|
|
8
|
Lencioni R: Loco-regional treatment of
hepatocellular carcinoma. Hepatology. 52:762–773. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lai CL, Chien RN, Leung NW, et al: A
one-year trial of lamivudine for chronic hepatitis B. Asia
Hepatitis Lamivudine Study Group. N Engl J Med. 339:61–68.
1998.PubMed/NCBI
|
|
10
|
Dienstag JL, Schiff ER, Wright TL, et al:
Lamivudine as initial treatment for chronic hepatitis B in the
United States. N Engl J Med. 341:1256–1263. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lok AS, Lai CL, Leung N, et al: Long-term
safety of lamivudine treatment in patients with chronic hepatitis
B. Gastroenterology. 125:1714–1722. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Marcellin P, Chang TT, Lim SG, et al:
Adefovir dipivoxil for the treatment of hepatitis B e
antigen-positive chronic hepatitis B. N Engl J Med. 348:808–816.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hadziyannis SJ, Tassopoulos NC, Heathcote
EJ, et al: Adefovir Dipivoxil 438 Study Group: Adefovir dipivoxil
for the treatment of hepatitis B e antigen-negative chronic
hepatitis B. N Engl J Med. 348:800–807. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chang TT, Gish RG, de Man R, et al: BEHoLD
AI463022 Study Group: A comparison of entecavir and lamivudine for
HBeAg-positive chronic hepatitis B. N Engl J Med. 354:1001–1110.
2006. View Article : Google Scholar
|
|
15
|
Lai CL, Shouval D, Lok AS, et al: BEHoLD
AI463027 Study Group: Entecavir versus lamivudine for patients with
HBeAg-negative chronic hepatitis B. N Engl J Med. 354:1011–1120.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zoulim F: Hepatitis B virus resistance to
antiviral drugs: where are we going? Liver Int. 31(Suppl 1):
S111–S116. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Leung N, Peng CY, Hann HW, et al: Early
hepatitis B virus DNA reduction in hepatitis B e antigen-positive
patients with chronic hepatitis B: A randomized international study
of entecavir versus adefovir. Hepatology. 49:72–79. 2009.
View Article : Google Scholar
|
|
18
|
Chang TT, Lai CL, Kew Yoon S, et al:
Entecavir treatment for up to 5 years in patients with hepatitis B
e antigen-positive chronic hepatitis B. Hepatology. 51:422–430.
2010.PubMed/NCBI
|
|
19
|
Ide T, Sata M, Chayama K, et al:
Evaluation of long-term entecavir treatment in stable chronic
hepatitis B patients switched from lamivudine therapy. Hepatol Int.
4:594–600. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wong GL, Chan HL, Mak CH, et al: Entecavir
treatment reduces hepatic events and deaths in chronic hepatitis B
patients with liver cirrhosis. Hepatology. Feb 6–2013.(Epub ahead
of print). View Article : Google Scholar
|
|
21
|
Hosaka T, Suzuki F, Kobayashi M, et al:
Long-term entecavir treatment reduces hepatocellular carcinoma
incidence in patients with hepatitis B virus infection. Hepatology.
58:98–107. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shakado S, Watanabe H, Tanaka T, et al:
Combination therapy of lamivudine and adefovir in Japanese patients
with chronic hepatitis B. Hepatol Int. 2:361–369. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ohishi W and Chayama K: Treatment of
chronic hepatitis B with nucleos(t)ide analogues. Hepatol Res.
42:219–225. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bruix J and Sherman M: Practice Guidelines
Committee, American Association for the Study of Liver Diseases:
Management of hepatocellular carcinoma. Hepatology. 42:1208–1236.
2005. View Article : Google Scholar
|
|
25
|
No authors listed. The general rules for
the clinical and pathological study of primary liver cancer. Liver
Cancer Study Group of Japan. Jpn J Surg. 19:98–129. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lo CM, Liu CL, Chan SC, et al: A
randomized, controlled trial of postoperative adjuvant interferon
therapy after resection of hepatocellular carcinoma. Ann Surg.
245:831–842. 2007. View Article : Google Scholar
|
|
27
|
Chan AC, Chok KS, Yuen WK, et al: Impact
of antiviral therapy on the survival of patients after major
hepatectomy for hepatitis B virus-related hepatocellular carcinoma.
Arch Surg. 146:675–681. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Du Y, Su T, Ding Y and Cao G: Effects of
antiviral therapy on the recurrence of hepatocellular carcinoma
after curative resection or liver transplantation. Hepat Mon.
12:e60312012.PubMed/NCBI
|
|
29
|
Sun HC, Zhang W, Qin LX, et al: Positive
serum hepatitis B e antigen is associated with higher risk of early
recurrence and poorer survival in patients after curative resection
of hepatitis B-related hepatocellular carcinoma. J Hepatol.
47:684–690. 2007. View Article : Google Scholar
|
|
30
|
Yao D, Jiang D, Huang Z, et al: Abnormal
expression of hepatoma specific gamma-glutamyl transferase and
alteration of gamma-glutamyl transferase gene methylation status in
patients with hepatocellular carcinoma. Cancer. 88:761–769. 2000.
View Article : Google Scholar
|
|
31
|
Zhang JB, Chen Y, Zhang B, et al:
Prognostic significance of serum gamma-glutamyl transferase in
patients with intermediate hepatocellular carcinoma treated with
transcatheter arterial chemoembolization. Eur J Gastroenterol
Hepatol. 23:787–793. 2011. View Article : Google Scholar
|
|
32
|
Ono A, Suzuki F, Kawamura Y, et al:
Long-term continuous entecavir therapy in nucleos(t)ide-naïve
chronic hepatitis B patients. J Hepatol. 57:508–514.
2012.PubMed/NCBI
|
|
33
|
Huang G, Yang Y, Shen F, et al: Early
viral suppression predicts good postoperative survivals in patients
with hepatocellular carcinoma with a high baseline HBV-DNA load.
Ann Surg Oncol. 20:1482–1490. 2013. View Article : Google Scholar
|
|
34
|
Chen L, Zhang Q, Chang W, Du Y, Zhang H
and Cao G: Viral and host inflammation-related factors that can
predict the prognosis of hepatocellular carcinoma. Eur J Cancer.
48:1977–1987. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xia F, Lai EC, Lau WY, et al: High serum
hyaluronic acid and HBV viral load are main prognostic factors of
local recurrence after complete radiofrequency ablation of
hepatitis B-related small hepatocellular carcinoma. Ann Surg Oncol.
19:1284–1291. 2012. View Article : Google Scholar
|
